Chapter·PharmacologyAntifungals

TerbinafineDownloads

10Questions
10Flashcards
1Tables & Flowcharts

Study Materials

Practice

Sample Questions

1

You are seeing a patient in clinic who recently started treatment for active tuberculosis. The patient is currently being treated with rifampin, isoniazid, pyrazinamide, and ethambutol. The patient is not used to taking medicines and is very concerned about side effects. Specifically regarding the carbohydrate polymerization inhibiting medication, which of the following is a known side effect?

AVision loss

BParesthesias of the hands and feet

CCutaneous flushing

DArthralgias

EElevated liver enzymes

2

A scientist is studying the excretion of a novel toxin X by the kidney in order to understand the dynamics of this new substance. He discovers that this new toxin X has a clearance that is half that of inulin in a particular patient. This patient's filtration fraction is 20% and his para-aminohippuric acid (PAH) dynamics are as follows: Urine volume: 100 mL/min Urine PAH concentration: 30 mg/mL Plasma PAH concentration: 5 mg/mL Given these findings, what is the clearance of the novel toxin X?

A1,500 mL/min

B600 mL/min

C300 mL/min

D60 mL/min

E120 mL/min

3

A 65-year-old man comes to the physician for a routine health maintenance examination. He feels well. His most recent examination 2 years ago included purified protein derivative (PPD) skin testing and showed no abnormalities. He is a retired physician and recently came back from rural China where he completed a voluntary service at a local healthcare center. A PPD skin test is performed. Three days later, an induration of 12 mm is noted. An x-ray of the chest shows no abnormalities. He is started on a drug that inhibits the synthesis of mycolic acid. This patient is at greatest risk of developing which of the following adverse effects?

ACytochrome P-450 induction

BHyperuricemia

CLiver injury

DOptic neuropathy

ENephrotoxicity

+ 7 more in the PDF

More Antifungals downloads

Browse all chapters

View all